Frailty and checkpoint inhibitor toxicity in older patients with melanoma.

Publication Year: 2022

DOI:
10.1002/cncr.34230

PMCID:
PMC9325486

PMID:
35439334

Journal Information

Full Title: Cancer

Abbreviation: Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Disclosures José J. Koldenhof, reports institutional grants and consulting fees from Novartis outside the submitted work. Karijn P. M. Suijkerbuijk reports grants from AbbVie and Novartis; personal fees from Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis, and Pierre‐Fabre; and honoraria from Merck Sharpe & Dohme and Roche outside the submitted work. The remaining authors made no disclosures."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025